FIH-1 Antibodies

Santa Cruz Biotechnology delivers a wide array of FIH-1 monoclonal antibodies for research focused on understanding FIH-1's role in cellular processes. The monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). FIH-1, or Factor Inhibiting HIF-1, functions as a key regulator of the hypoxia-inducible factor (HIF) pathway, playing a significant role in cellular responses to low oxygen levels. Through hydroxylation of HIF-1α, FIH-1 modulates its activity and stability, influencing processes such as angiogenesis, metabolism, and cell survival. Research into FIH-1 continues to reveal its implications in various diseases, including cancer and ischemic conditions. Scientists can explore the complex interactions between FIH-1 and its molecular partners using specific detection methods. Understanding FIH-1's regulatory mechanisms provides valuable insights into cellular adaptation to hypoxic conditions. Investigating FIH-1's role in disease progression helps identify potential therapeutic targets. Santa Cruz Biotechnology monoclonal antibodies enable researchers to advance scientific understanding of hypoxia signaling pathways and their impact on human health.